In a study reported herein, the marketing approval dates of 214 drugs newly introduced into the world market from January 1990 through December 1994 were compared in 4 countries.
The analysis reveals that the United States and the United Kingdom have similar patterns of drug availability, although the United States has a number of therapies with significant public health benefits that are not yet available in the United Kingdom.
The findings also show thatthe United States outpaces both Germany and Japan in approving important new drugs.
Various strategies adopted by the Food and Drug Administration to expedite its pharmaceutical review process, including the use of industry user fees, are described.
Mots-clés Pascal : Médicament, Variété nouvelle, Disponibilité, Food and Drug Administration, Etude comparative, Analyse statistique, Royaume Uni, Europe, Allemagne, Japon, Asie, Etats Unis, Amérique du Nord, Amérique, Stratégie recherche, Prévention, Evaluation, Homme, Organisation santé
Mots-clés Pascal anglais : Drug, New variety, Availability, Food and Drug Administration, Comparative study, Statistical analysis, United Kingdom, Europe, Germany, Japan, Asia, United States, North America, America, Search strategy, Prevention, Evaluation, Human, Public health organization
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0065008
Code Inist : 002B02A06. Création : 21/05/1997.